Larimar Therapeutics (LRMR) risk factors
Item 1A of every Larimar Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors100 risks11 new8 dropped17 reworded
Cash of $136.9 million plus $107.6 million from a February 2026 offering funds operations into the second quarter of 2027. Net operating loss carryforwards increased from $198.2 million to $349.9 million. Regulatory risks center on the development and commercialization of lead candidate nomlabofusp for Friedreich's ataxia.
Filed Mar 19, 2026 - FY2024 10-K risk factors97 risks
Larimar has incurred substantial losses since inception with an accumulated deficit of $269.2 million as of December 31, 2024. The company relies entirely on the clinical success and regulatory approval of its single lead product candidate, nomlabofusp. Existing cash of $183.5 million is expected to fund operations into the second quarter of 2026.
Filed Mar 24, 2025